(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Deere & Company Surpasses Q2 Expectations, Foot Locker Falls Short, and Intercept Pharmaceuticals Stock Halted Amid FDA Review

  • May 19th, 2023
  • 563 views

Deere & Company (NYSE: DE) has released its second-quarter fiscal 2023 earnings per share (EPS) report, surpassing consensus expectations. The company reported an EPS of $9.65, exceeding the consensus estimate of $8.59.

John C. May, the chairman and chief executive officer of Deere, expressed satisfaction with the outstanding second-quarter results. He noted that Deere continues to benefit from favorable market conditions and an improving operating environment.

In pre-market trading, $DE is currently valued at $385.00, experiencing a significant increase of $14.48 (+3.91%).

On the other hand, Foot Locker, Inc. (NYSE: FL) has released its first-quarter 2023 earnings report, which fell short of consensus expectations. The company reported an EPS of $0.70, lower than the consensus estimate of $0.81, and a decline in comparable-store sales by 9.1%, primarily attributed to macroeconomic headwinds -including lower income tax refunds in the United States-.

In pre-market trading, $FL is currently valued at $31.89, showing a significant decrease of $9.63 (-23.19%).

In other news, NASDAQ has halted trading of Intercept Pharmaceuticals, Inc.'s (Nasdaq: ICPT) common stock. The reason behind this halt is the ongoing meeting of the U.S. Food and Drug Administration's (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC), which is currently reviewing the use of obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

Please note that the stock prices and pre-market movements mentioned here are for illustrative purposes and may not reflect the current market conditions at the time of reading.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13